By Darren Smith, Weekend Contributor
Following his arrest this week for alleged securities fraud, Turing Pharmaceuticals CEO Martin Shkreli resigned his office.
Turing garnered infamy for the 5000 percent price increase of Daraprim, a $13.50 medication indicated for patients requiring treatment of Toxoplasma gondii–an opportunistic pathogen afflicting the immune-compromised such as AIDS patients. Monthly treatment cost now associated with the drug can be upwards of seventy-five thousand dollars. See previous articles HERE and HERE.
Interim CEO Ron Tiles thanked the 32-year-old for “helping us build Turing Pharmaceuticals into the dynamic research-focused company it is today.”
Continue reading “Embattled Turing Pharmaceuticals CEO Martin Shkreli Resigns”